Empowering Women's Health: Daré Bioscience at J.P. Morgan Conference

Empowering Women's Health: Daré Bioscience at J.P. Morgan Conference

The panel will discuss the value proposition for investing in women’s health.

J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the significance of innovation and increased attention on women’s health.

Daré Bioscience, Inc. (NASDAQ: DARE), a frontrunner in advancing women's health innovations, has announced that Sabrina Martucci Johnson, President and CEO, will participate in the ARPA-H | Investing in Women’s Health panel at the esteemed Women’s Health Series during the 43rd Annual J.P. Morgan Healthcare Conference. This impactful panel is scheduled for a date soon, and it will shed light on vital topics such as Women’s Health Care Future and Funding Flow.

Ms. Johnson expressed enthusiasm regarding the focus on women’s health as the year begins, reflecting on significant achievements like the recent collaborative Nasdaq closing bell ringing with the Advanced Research Projects Agency for Health (ARPA-H). “Through these initiatives, we aim to amplify discussions surrounding women's health and advocate for enhanced investment opportunities,” remarked Ms. Johnson. She emphasized that Daré stands at the forefront of innovation with a diverse pipeline, creating disruptive therapeutic candidates across contraception, sexual health, menopause, fertility, and more.

Additionally, Johnson will feature at an event organized by Grant Engine on the same conference. Here, she will highlight two significant funding awards that Daré has secured: approximately $10 million each from non-dilutive funding sources aimed at groundbreaking initiatives in women’s health.

Highlights include a foundation award dedicated to developing a groundbreaking non-hormonal contraceptive candidate and securing the ARPA-H Sprint for Women’s Health award for innovations aimed at HPV treatment to thwart cervical cancer.

About Daré Bioscience

Daré Bioscience is dedicated to innovating products that enhance women’s health. The company focuses on developing and delivering an array of unique therapies designed specifically for women’s needs across multiple health aspects, including fertility, sexual health, and menopause.

Among its noteworthy offerings is XACIATO™ (clindamycin phosphate) vaginal gel 2%, the first FDA-approved product from Daré’s pipeline, aimed at treating bacterial vaginosis in females aged 12 and above. Under a global license agreement with Organon, XACIATO™ represents a significant milestone for Daré. For further insights, interested readers can visit www.xaciato.com.

Beyond its currently available products, Daré’s pipeline highlights several first-in-category candidates in clinical development, including Ovaprene®, a novel hormone-free monthly contraceptive bound for the U.S. market under a license agreement with Bayer. Another potential product is Sildenafil Cream, 3.6%, designed to treat female sexual arousal disorder (FSAD). The company is also developing DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy in menopausal women.

In terms of recognition, Daré has made notable appearances on esteemed lists such as the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma. The CEO’s leadership was acknowledged in 2023 as one of Fierce Pharma’s Most Influential People in Biopharma, illustrating Daré's commitment to women’s health innovation. Daré was also recognized as the top small company in the San Diego Business Journal’s 2023 Best Places to Work Awards.

Communication and Engagement

Daré Bioscience maintains transparency and keeps its stakeholders informed about financial performance, product development, and clinical trials via their Investor Relations website and through public releases. They encourage all interested parties including investors and the media to stay updated through social media channels highlighting their latest developments. Daily insights can be followed on X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience.

Frequently Asked Questions

What is the key focus of the panel Daré Bioscience will participate in?

The panel, part of the Women’s Health Series, will discuss investing in women’s health and highlight the importance of innovation in this sector.

When will the panel take place?

The panel is scheduled to occur on a specific day soon at the J.P. Morgan Healthcare Conference, though an exact date hasn't been provided.

What innovative products does Daré Bioscience offer?

Daré’s portfolio includes XACIATO™, a vaginal gel, and other products under development like Ovaprene® and Sildenafil Cream for women’s health issues.

What awards has Daré received recently?

Daré has secured non-dilutive funding awards aimed at advancing women’s health solutions, including a substantial foundation award and an ARPA-H award.

How can I stay updated on Daré Bioscience's developments?

You can follow Daré’s updates through their Investor Relations website and their social media channels on X.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.